The IPO market is expected to remain active in the week ahead with nine IPOs scheduled to raise $2.7 billion.
Canadian digital service provider TELUS International (TIXT) plans to raise $800 million at a $6.4 billion market cap. The...read more
In a staggering start to 2021, two biotechs and 28 SPACs raised over $7.1 billion in the first week of the new year. Activity should remain high as new filings continued to flood the IPO pipeline. Chinese cancer biotech ...read more
Cullinan Management, a Phase 1/2a biotech developing and investing in oncology therapies, raised $250 million by offering 11.9 million shares at $21, above the upwardly revised range of $19 to $20. The company originally planned to offer 8.3 million shares at...read more
Cullinan Management, a Phase 1/2a biotech developing and investing in oncology therapies, raised the proposed deal size for its upcoming IPO on Wednesday. The Cambridge, MA-based company now plans to raise $195 million by offering 10 million shares at a...read more
US IPO Week Ahead: Canadian IT and German chemicals lead a diverse 9 IPO week
The IPO market is expected to remain active in the week ahead with nine IPOs scheduled to raise $2.7 billion. Canadian digital service provider TELUS International (TIXT) plans to raise $800 million at a $6.4 billion market cap. The...read more
US IPO Weekly Recap: The new year kicks off with 2 biotech IPOs and a tidal wave of SPACs
In a staggering start to 2021, two biotechs and 28 SPACs raised over $7.1 billion in the first week of the new year. Activity should remain high as new filings continued to flood the IPO pipeline. Chinese cancer biotech ...read more
Oncology biotech Cullinan Management prices further upsized IPO at $21, above the upwardly revised range
Cullinan Management, a Phase 1/2a biotech developing and investing in oncology therapies, raised $250 million by offering 11.9 million shares at $21, above the upwardly revised range of $19 to $20. The company originally planned to offer 8.3 million shares at...read more
Oncology biotech Cullinan Management increases deal size by 30% ahead of $195 million IPO
Cullinan Management, a Phase 1/2a biotech developing and investing in oncology therapies, raised the proposed deal size for its upcoming IPO on Wednesday. The Cambridge, MA-based company now plans to raise $195 million by offering 10 million shares at a...read more